A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma With Preserved Liver Function. HCRN: GI15-225

Inclusion Criteria
Locally advanced HCC
No evidence of extrahepatic metastatic disease
Not eligible for surgical resection or liver transplant or have refused such procedures
Demonstrate adequate organ function
Exclusion Criteria
Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of study registration
Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to registration
Active autoimmune disease that has required systemic treatment in the past 2 years
Known history of active TB
Hypersensitivity to pembrolizumab or any of its excipients
Known history of HIV
Untreated active HBV
Dual infection with HBV/HCV or other hepatitis combinations at study entry
Known history of, or any evidence of active, non-infectious pneumonitis
History of organ transplantation including previous history of liver transplantation
Active infection requiring systemic therapy
Pregnant or breastfeeding